• Home
The News Universe
No Result
View All Result
No Result
View All Result
The News Universe
No Result
View All Result

Wisezone launches ZONE HSS1, a screen-free AI wearable built for real life

admin by admin
September 2, 2025
in Uncategorized
0
Kickstarter campaign goes live Sep 2, 2025 at 8:00 AM ET

Seoul, South Korea – Sep 2, 2025 – Wisezone (CT5 Inc.) today announced ZONE HSS1, a screen-free AI wearable that delivers hands-free assistance, two-person translation, and privacy-first vision—without face-mounted displays. The device combines open-ear speakers with a detachable in-ear earbud so users can move seamlessly from social awareness to private listening. The Kickstarter campaign launches today at 8:00 AM ET.

“People want the benefits of AI without a screen in their face,” said Jiwon Kang, founder and CEO of Wisezone. “ZONE HSS1 keeps you present with others while giving you translation, guidance, and context when you need it. It’s a smarter, safer alternative to smart glasses.”

Key features include hybrid audio (open ear + in ear), two-person translation by sharing the earbud, privacy-first adjustable camera tilt, and all-day battery designed for up to 24 hours of mixed use (with camera up to ~15 minutes continuous). The product is Made in Korea with a patent-pending architecture.

Backers can learn more and pledge on Kickstarter:

https://www.kickstarter.com/projects/2050126361/beyond-ai-glasses-worlds-first-multi-user-ai-wearable

About Wisezone (CT5 Inc.)

Wisezone builds human-centered AI wearables that are screen-free, privacy-first, and built for real life. Headquartered in Korea, Wisezone combines design, engineering, and an expanding IP portfolio to shape safer, more natural ways to interact with AI.

Media Contact
Company Name: Wise Zone Inc.
Contact Person: Jiwon Kang
Email: Send Email
Country: South Korea
Website: https://www.wisezone.ai/

Previous Post

Polycythemia Vera Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

Next Post

TCR Therapy Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

Next Post

TCR Therapy Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.

No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.